Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept

Series C round led by Deep Track Capital with participation from additional new and existing investors

Financing will fund early-to-mid-stage clinical studies for ATTO-1310 in chronic pruritus and ATTO-3712 in atopic dermatitis, and multiple earlier-stage multi-specific programs

SAN CARLOS, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- Attovia Therapeutics, a privately-held, clinical-stage biopharma company developing treatments for immune-mediated diseases with high unmet patient need, today announced the close of a $90 million Series C financing. The funding round was led by Deep Track Capital with participation from new investors including Vida Ventures, Sanofi Ventures, and Mirae Asset Capital Life Science, and ongoing support from existing investors including Frazier Life Sciences, venBio, Goldman Sachs Alternatives, Nextech Ventures, Cormorant Asset Management, EcoR1 Capital, Marshall Wace, and Illumina Ventures. In conjunction with the financing, Rebecca Luse, Managing Director at Deep Track Capital, will join the Company's Board of Directors.

Proceeds from the financing, along with the Company's existing cash and investments, will be used to advance Attovia's lead assets, ATTO-1310 and ATTO-3712, through clinical proof-of-concept, with the aim of achieving best-in-disease efficacy for the treatment of chronic pruritus and atopic dermatitis. The funds will also enable focused ...